<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--NeoClarus - iFile Suite version 3.4434-->
<xbrl xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:wndm="http://www.wmgtech.com/20110930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xhtml="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:ISO4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:href="wndm-20110930.xsd" />
  <dei:AmendmentFlag id="AmendmentFlag.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="CurrentFiscalYearEndDate.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus id="DocumentFiscalPeriodFocus.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus id="DocumentFiscalYearFocus.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate id="DocumentPeriodEndDate.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">2011-09-30</dei:DocumentPeriodEndDate>
  <dei:DocumentType id="DocumentType.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey id="EntityCentralIndexKey.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">0000714256</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="EntityCommonStockSharesOutstanding.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="UShares" decimals="0">58027286</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus id="EntityCurrentReportingStatus.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory id="EntityFilerCategory.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="EntityRegistrantName.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">WOUND MANAGEMENT TECHNOLOGIES, INC.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers id="EntityVoluntaryFilers.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer id="EntityWellKnownSeasonedIssuer.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">No</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:AccountsPayableCurrent id="AccountsPayableCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">226341</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="AccountsPayableCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">321352</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">74547</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="AccountsReceivableNetCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">450142</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="AccruedLiabilitiesCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">547155</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent id="AccruedLiabilitiesCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">458218</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedRoyaltiesCurrent id="AccruedRoyaltiesCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">334488</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:AccruedRoyaltiesCurrent id="AccruedRoyaltiesCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">428238</us-gaap:AccruedRoyaltiesCurrent>
  <us-gaap:AdditionalPaidInCapital id="AdditionalPaidInCapital.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">34752970</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital id="AdditionalPaidInCapital.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">26056408</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="AmortizationOfFinancingCostsAndDiscounts.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">498436</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="AmortizationOfFinancingCostsAndDiscounts.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-51587</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:Assets id="Assets.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">7777050</us-gaap:Assets>
  <us-gaap:Assets id="Assets.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">6783327</us-gaap:Assets>
  <us-gaap:AssetsCurrent id="AssetsCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">1798350</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="AssetsCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">850092</us-gaap:AssetsCurrent>
  <us-gaap:AssetsNoncurrent id="AssetsNoncurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">5978700</us-gaap:AssetsNoncurrent>
  <us-gaap:AssetsNoncurrent id="AssetsNoncurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">5933235</us-gaap:AssetsNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">105821</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">50835</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="CashAndCashEquivalentsAtCarryingValue.3019.0.0" contextRef="as-of-2010-09-30.3019.0.0.0" unitRef="USD" decimals="0">37753</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">54986</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="CashAndCashEquivalentsPeriodIncreaseDecrease.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">37753</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="CommonStockParOrStatedValuePerShare.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="UPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="UShares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="CommonStockSharesAuthorized.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="UShares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="UShares" decimals="0">58031375</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="CommonStockSharesIssued.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="UShares" decimals="0">41316930</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="UShares" decimals="0">58027286</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="CommonStockSharesOutstanding.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="UShares" decimals="0">41312841</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable id="CommonStockShareSubscribedButUnissuedSubscriptionsReceivable.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">-52398</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
  <us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable id="CommonStockShareSubscribedButUnissuedSubscriptionsReceivable.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">-292074</us-gaap:CommonStockShareSubscribedButUnissuedSubscriptionsReceivable>
  <us-gaap:CommonStockValue id="CommonStockValue.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">58031</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="CommonStockValue.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">41317</us-gaap:CommonStockValue>
  <us-gaap:ConvertibleDebtNoncurrent id="ConvertibleDebtNoncurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">509649</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent id="ConvertibleDebtNoncurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">435346</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:CostOfGoodsSold id="CostOfGoodsSold.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">373505</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="CostOfGoodsSold.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">552658</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="CostOfGoodsSold.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">296641</us-gaap:CostOfGoodsSold>
  <us-gaap:CostOfGoodsSold id="CostOfGoodsSold.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">345455</us-gaap:CostOfGoodsSold>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="CurrentIncomeTaxExpenseBenefit.3013.0.0" xsi:nil="true" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="CurrentIncomeTaxExpenseBenefit.3014.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="CurrentIncomeTaxExpenseBenefit.3015.0.0" xsi:nil="true" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="CurrentIncomeTaxExpenseBenefit.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="DebtConversionConvertedInstrumentSharesIssued1.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="UShares" decimals="0">1282664</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 id="DebtConversionConvertedInstrumentSharesIssued1.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="UShares" decimals="0">2498401</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet id="DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">252969</us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet>
  <us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet id="DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-1128914</us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet>
  <us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet id="DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">-462545</us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet>
  <us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet id="DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-1195219</us-gaap:DebtorReorganizationItemsGainLossOnSettlementOfOtherClaimsNet>
  <us-gaap:DeferredFinanceCostsNoncurrentNet id="DeferredFinanceCostsNoncurrentNet.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">81943</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:DeferredFinanceCostsNoncurrentNet id="DeferredFinanceCostsNoncurrentNet.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">89170</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="DeferredIncomeTaxExpenseBenefit.3013.0.0" xsi:nil="true" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="DeferredIncomeTaxExpenseBenefit.3014.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="DeferredIncomeTaxExpenseBenefit.3015.0.0" xsi:nil="true" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="DeferredIncomeTaxExpenseBenefit.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:DepreciationAndAmortization id="DepreciationAndAmortization.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">117453</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="DepreciationAndAmortization.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">353165</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="DepreciationAndAmortization.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">135618</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="DepreciationAndAmortization.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">371496</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="DepreciationDepletionAndAmortization.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">353165</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="DepreciationDepletionAndAmortization.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">353818</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="UPerShare" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="UPerShare" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="UPerShare" decimals="2">-0.05</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="EarningsPerShareBasicAndDiluted.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="UPerShare" decimals="1">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="GainsLossesOnExtinguishmentOfDebt.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">1128914</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="GainsLossesOnExtinguishmentOfDebt.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">1195219</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:GrossProfit id="GrossProfit.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">-239664</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">744293</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">-184989</us-gaap:GrossProfit>
  <us-gaap:GrossProfit id="GrossProfit.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-52846</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">-1066016</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-7008903</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">-1685279</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-3594375</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxesPaidNet id="IncomeTaxesPaidNet.3014.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncomeTaxesPaidNet id="IncomeTaxesPaidNet.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:IncreaseDecreaseInAccountsPayable id="IncreaseDecreaseInAccountsPayable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-95011</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="IncreaseDecreaseInAccountsPayable.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">23956</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">375595</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="IncreaseDecreaseInAccountsReceivable.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-50893</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet id="IncreaseDecreaseInAccruedInterestReceivableNet.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-106138</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet id="IncreaseDecreaseInAccruedInterestReceivableNet.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-90750</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="IncreaseDecreaseInAccruedLiabilities.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">88937</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities id="IncreaseDecreaseInAccruedLiabilities.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-20430</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent id="IncreaseDecreaseInDueFromRelatedPartiesCurrent.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-106741</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent id="IncreaseDecreaseInDueFromRelatedPartiesCurrent.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-25614</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent id="IncreaseDecreaseInDueToRelatedPartiesCurrent.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">28793</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent id="IncreaseDecreaseInDueToRelatedPartiesCurrent.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">149311</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInInterestPayableNet id="IncreaseDecreaseInInterestPayableNet.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">86210</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInterestPayableNet id="IncreaseDecreaseInInterestPayableNet.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">18290</us-gaap:IncreaseDecreaseInInterestPayableNet>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-15424</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories id="IncreaseDecreaseInInventories.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">43218</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-45000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-172587</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInRoyaltiesPayable id="IncreaseDecreaseInRoyaltiesPayable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-93750</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
  <us-gaap:IncreaseDecreaseInRoyaltiesPayable id="IncreaseDecreaseInRoyaltiesPayable.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">280559</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="IntangibleAssetsNetExcludingGoodwill.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">3758500</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill id="IntangibleAssetsNetExcludingGoodwill.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">4110859</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestExpense id="InterestExpense.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">-69282</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-206104</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">-318696</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="InterestExpense.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-484757</us-gaap:InterestExpense>
  <us-gaap:InterestPaid id="InterestPaid.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">91101</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="InterestPaid.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">22473</us-gaap:InterestPaid>
  <us-gaap:InterestReceivableNoncurrent id="InterestReceivableNoncurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">231388</us-gaap:InterestReceivableNoncurrent>
  <us-gaap:InterestReceivableNoncurrent id="InterestReceivableNoncurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">125250</us-gaap:InterestReceivableNoncurrent>
  <us-gaap:InventoryNet id="InventoryNet.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">412608</us-gaap:InventoryNet>
  <us-gaap:InventoryNet id="InventoryNet.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">290034</us-gaap:InventoryNet>
  <us-gaap:InvestmentIncomeInterest id="InvestmentIncomeInterest.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">77179</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="InvestmentIncomeInterest.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">212879</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="InvestmentIncomeInterest.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">47610</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest id="InvestmentIncomeInterest.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">116364</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="IssuanceOfStockAndWarrantsForServicesOrClaims.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">161600</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims id="IssuanceOfStockAndWarrantsForServicesOrClaims.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">218282</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:Liabilities id="Liabilities.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">2964209</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Liabilities.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">3914535</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">7777050</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="LiabilitiesAndStockholdersEquity.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">6783327</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">2454560</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="LiabilitiesCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">3479189</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiquidityDisclosureGoingConcernNote id="LiquidityDisclosureGoingConcernNote.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 2 - GOING CONCERN&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Company has current liabilities in excess of current assets and has a stockholders&amp;#39; deficiency. The Company has had limited operations and has not been able to develop an ongoing, reliable source of revenue to fund its existence.&amp;nbsp;&amp;nbsp;The Company&amp;#39;s day-to-day expenses have been covered by proceeds obtained, and services paid by, the issuance of stock and notes payable.&amp;nbsp;&amp;nbsp;The adverse effect on the Company&amp;#39;s results of operations due to its lack of capital resources can be expected to continue until such time as the Company is able to generate additional capital from other sources.&amp;nbsp;&amp;nbsp;These conditions raise substantial doubt about the Company&amp;#39;s ability to continue as a going concern.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; These unaudited interim condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.&amp;nbsp;&amp;nbsp;The continuation of the Company as a going concern is dependent upon the success of the Company in obtaining additional funding and the success of its future operations.&amp;nbsp;&amp;nbsp;&amp;nbsp;The ability of the Company to achieve these objectives cannot be determined at this time.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:LiquidityDisclosureGoingConcernNote>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">1592713</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="NetCashProvidedByUsedInFinancingActivities.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">1907673</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-954422</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="NetCashProvidedByUsedInInvestingActivities.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-623662</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-583305</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="NetCashProvidedByUsedInOperatingActivities.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-1246258</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-7008903</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="NetIncomeLoss.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-3594375</us-gaap:NetIncomeLoss>
  <us-gaap:NotesAndLoansReceivableNetNoncurrent id="NotesAndLoansReceivableNetNoncurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">1750000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
  <us-gaap:NotesAndLoansReceivableNetNoncurrent id="NotesAndLoansReceivableNetNoncurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">1500000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent id="NotesPayableRelatedPartiesClassifiedCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">419577</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
  <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent id="NotesPayableRelatedPartiesClassifiedCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">1818561</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
  <us-gaap:NotesReceivableRelatedPartiesCurrent id="NotesReceivableRelatedPartiesCurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">1104008</us-gaap:NotesReceivableRelatedPartiesCurrent>
  <us-gaap:NotesReceivableRelatedPartiesCurrent id="NotesReceivableRelatedPartiesCurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">13782</us-gaap:NotesReceivableRelatedPartiesCurrent>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">-751844</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-1811785</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">-745398</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="OperatingIncomeLoss.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-1824513</us-gaap:OperatingIncomeLoss>
  <us-gaap:OriginationOfNotesReceivableFromRelatedParties id="OriginationOfNotesReceivableFromRelatedParties.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-5284666</us-gaap:OriginationOfNotesReceivableFromRelatedParties>
  <us-gaap:OriginationOfNotesReceivableFromRelatedParties id="OriginationOfNotesReceivableFromRelatedParties.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-1280037</us-gaap:OriginationOfNotesReceivableFromRelatedParties>
  <us-gaap:OtherNoncashExpense id="OtherNoncashExpense.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">201387</us-gaap:OtherNoncashExpense>
  <us-gaap:OtherNoncashExpense id="OtherNoncashExpense.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">22019</us-gaap:OtherNoncashExpense>
  <us-gaap:PaymentsToAcquireBusinessesGross id="PaymentsToAcquireBusinessesGross.3014.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PaymentsToAcquireBusinessesGross id="PaymentsToAcquireBusinessesGross.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-100000</us-gaap:PaymentsToAcquireBusinessesGross>
  <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent id="PrepaidExpenseAndOtherAssetsNoncurrent.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">156869</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent id="PrepaidExpenseAndOtherAssetsNoncurrent.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">107150</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.3014.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromConvertibleDebt id="ProceedsFromConvertibleDebt.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">570000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">954699</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="ProceedsFromIssuanceOfCommonStock.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">149998</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromNotesPayable id="ProceedsFromNotesPayable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">3213000</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromNotesPayable id="ProceedsFromNotesPayable.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">457475</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromRepaymentsOfBankOverdrafts id="ProceedsFromRepaymentsOfBankOverdrafts.3014.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:ProceedsFromRepaymentsOfBankOverdrafts id="ProceedsFromRepaymentsOfBankOverdrafts.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-4363</us-gaap:ProceedsFromRepaymentsOfBankOverdrafts>
  <us-gaap:ProfitLoss id="ProfitLoss.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">-1066016</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ProfitLoss.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-7008903</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ProfitLoss.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">-1685279</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="ProfitLoss.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-3594375</us-gaap:ProfitLoss>
  <us-gaap:PropertyPlantAndEquipmentNet id="PropertyPlantAndEquipmentNet.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">806</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="RelatedPartyTransactionsDisclosureTextBlock.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 8 - RELATED PARTY TRANSACTIONS&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Company&amp;#39;s corporate office is located in Fort Worth, Texas, in a space leased by HEB, LLC.&amp;nbsp;&amp;nbsp;The Company shares the space with the VHGI corporate office and other HEB affiliated companies.&amp;nbsp;&amp;nbsp;The Fort Lauderdale office occupied by WCI is also leased by HEB and shared with a subsidiary of VHGI.&amp;nbsp;&amp;nbsp;The Company reimburses HEB for the cost of both office spaces.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Company also reimburses HEB for the cost of accounting and administrative services provided to the Company by employees of HEB. Additionally, the Company pays HEB for the actual costs of health benefits provided to Company employees through HEB.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentOfNotesReceivableFromRelatedParties id="RepaymentOfNotesReceivableFromRelatedParties.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">4330244</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
  <us-gaap:RepaymentOfNotesReceivableFromRelatedParties id="RepaymentOfNotesReceivableFromRelatedParties.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">756375</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
  <us-gaap:RepaymentsOfNotesPayable id="RepaymentsOfNotesPayable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-1960498</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfNotesPayable id="RepaymentsOfNotesPayable.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-483302</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">-29933723</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="RetainedEarningsAccumulatedDeficit.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">-22924820</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Revenues id="Revenues.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">133841</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">1296951</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">111652</us-gaap:Revenues>
  <us-gaap:Revenues id="Revenues.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">292609</us-gaap:Revenues>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="SellingGeneralAndAdministrativeExpense.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">394727</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="SellingGeneralAndAdministrativeExpense.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">2202913</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="SellingGeneralAndAdministrativeExpense.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">424791</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense id="SellingGeneralAndAdministrativeExpense.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">1400171</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="SignificantAccountingPoliciesTextBlock.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Basis of Presentation&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The terms "WMT," "we," "the Company," and "us" as used in this report refer to Wound Management Technologies, Inc.&amp;nbsp;&amp;nbsp;The accompanying unaudited condensed consolidated balance sheet as of September 30, 2011 and unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2011 and 2010 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&amp;nbsp;&amp;nbsp;Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements.&amp;nbsp;&amp;nbsp;In the opinion of management of WMT, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.&amp;nbsp;&amp;nbsp;Operating results for the nine month period ended September 30, 2011 are not necessarily indicative of the results that may be expected for the year ending December 31, 2011 or any other period.&amp;nbsp;&amp;nbsp;These financial statements and notes should be read in conjunction with the financial statements for each of the two years ended December 31, 2010 and December 31, 2009, included in the Company&amp;#39;s Annual Report on Form 10-K.&amp;nbsp;&amp;nbsp;The accompanying audited consolidated balance sheet as of December 31, 2010 has been included for comparison purposes in the accompanying balance sheet.&amp;nbsp;&amp;nbsp;Certain prior year amounts have been reclassified to conform to current year presentation.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Principles of Consolidation&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The accompanying consolidated financial statements include the accounts of WMT and its wholly-owned subsidiaries:&amp;nbsp;&amp;nbsp;Wound Care Innovations, LLC ("WCI"), a Nevada limited liability company; BioPharma Management Technologies, Inc. ("BioPharma"), a Texas corporation; Resorbable Orthopedic Products, LLC ("Resorbable"), a Texas limited liability company; and Secure eHealth, LLC ("SeHealth"), a Nevada limited liability company.&amp;nbsp;&amp;nbsp;All intercompany accounts and transactions have been eliminated.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Fair Value Measurements&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; As defined in Accounting Standards Codification ("ASC") Topic No. 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable.&amp;nbsp;&amp;nbsp;&amp;nbsp;ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).&amp;nbsp;&amp;nbsp;&amp;nbsp;This fair value measurement framework applies at both initial and subsequent measurement.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The three levels of the fair value hierarchy defined by ASC Topic No. 820 are as follows:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Level 1 - Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Level 2 - Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Level 3 - Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management&amp;#39;s best estimate of fair value.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; There are no financial instruments existing at September 30, 2011 that are subject to fair value measurement.&amp;nbsp;&amp;nbsp;Our intangible assets have been valued using this accounting treatment and a description of the methodology used, including the valuation category, is described below in Note 6 "Intangible Assets."&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Beneficial Conversion Feature of Convertible Notes Payable&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The convertible feature of certain notes payable provides for a rate of conversion that is below the market value of the Company&amp;#39;s common stock. Such a feature is normally characterized as a "Beneficial Conversion Feature" ("BCF"). In accordance with ASC Topic No. 470-20-25-4, the intrinsic value of the embedded beneficial conversion feature present in a convertible instrument shall be recognized separately at issuance by allocating a portion of the debt equal to the intrinsic value of that feature to additional paid in capital.&amp;nbsp;&amp;nbsp;When applicable, the Company records the estimated fair value of the BCF in the condensed consolidated financial statements as a discount from the face amount of the notes. Such discounts are accreted to interest expense over the term of the notes using the effective interest method.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockholdersEquity id="StockholdersEquity.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">4812841</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="StockholdersEquity.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">2868792</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="StockholdersEquityNoteDisclosureTextBlock.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 7 - STOCKHOLDERS&amp;#39; EQUITY&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Preferred Stock&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; As of May 2008, all shares of Series A Preferred Stock of the Company were converted into common stock. There are currently 5,000,000 shares of Preferred Stock authorized, with no shares of Series A Preferred Stock currently issued or outstanding.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Effective June 24, 2010, the Company filed a Certificate of Designations, Number, Voting Power, Preferences and Rights of Series B Convertible Redeemable Preferred Stock (the "Certificate") with the Texas Secretary of State, designating 75,000 shares of Series B Preferred Stock, par value $10.00 per share (the "Series B&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;nbsp;&lt;/font&gt; Preferred Stock&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;"&lt;/font&gt;). The Series B Preferred Stock ranks senior to shares of all other common and preferred stock with respect to dividends, distributions, and payments upon dissolution.&amp;nbsp;&amp;nbsp;Each of the Series B Shares is convertible at the option of the holder into shares of common stock as provided in the Certificate.&amp;nbsp;&amp;nbsp;There are currently no shares of Series B Preferred Stock issued or outstanding.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Common Stock&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Company is authorized to issue 100,000,000 shares of common stock, par value of $0.001 per share.&amp;nbsp;&amp;nbsp;These shares have full voting rights.&amp;nbsp;&amp;nbsp;As of September 30, 2011, there were 58,031,375 shares of common stock issued and 58,027,286 shares outstanding.&amp;nbsp;&amp;nbsp;&amp;nbsp;At December 31, 2010, there were 41,316,930 shares of common stock issued and 41,312,841 shares outstanding.&amp;nbsp;&amp;nbsp;The Company holds 4,089 shares as treasury stock.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; During the three months ended March 31, 2011, the Company entered into various Subscription Agreements with unrelated parties (the "Investors") to purchase 3,473,300 Units at a purchase price of $.25 per Unit ("Units"), with each Unit consisting of:&amp;nbsp;&amp;nbsp;&amp;nbsp;(i) one share of the Company&amp;#39;s common stock and (ii) a warrant to purchase one share of the Company&amp;#39;s common stock (the "Warrants").&amp;nbsp;&amp;nbsp;&amp;nbsp;One-half of the Warrants have an exercise&amp;nbsp;price of $1.00 per share of common stock and one-half of the Warrants have an exercise&amp;nbsp;price of $.50 per share of common stock.&amp;nbsp;&amp;nbsp;The Warrants may be exercised at any time over a three-year period.&amp;nbsp;&amp;nbsp;The total amount paid for the Units was $868,700, of which $434,350 was recorded for the sale of stock and $434,350 was recorded for the sale of warrants.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; In addition, during the three months ended March 31, 2011, the Company issued 4,169,213 shares of common stock in payment of related party debt in the amount of $778,108 and 5,400,000 shares of common stock in payment of unrelated party debt in the amount of $322,000.&amp;nbsp;&amp;nbsp;The Company also issued 164,286 shares of common stock as payment for cable television spots and 200,000 shares in payment of consulting and services.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Debt related costs in the amount of $405,580 were paid with the issuance of 733,043 shares of common stock.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; During the three months ending June 30, 2011, the Company entered into various Subscription Agreements to various unrelated parties and issued 244,000 shares of common stock and 260,000 warrants, half with an exercise price of $1.00 and half with an exercise price of $0.50 in consideration for payments of $76,000 in the aggregate. The Company also issued 80,000 shares for consulting services with a value of $49,600 and 400,000 shares of stock in payment of placement fees with a value of $268,000. The Company issued an additional 300,000 shares in payment of related party debt and 80,000 shares in payment of unrelated party debt.&amp;nbsp;&amp;nbsp;The Company also issued 350,000 shares for loan origination fees.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; During the three months ended September 30, 2011, the Company converted $52,000 of debt and accrued interest into 235,603 shares of common stock. The Company also issued 845,000 shares of common stock for loan origination fees valued at $567,700.&amp;nbsp;&amp;nbsp;Additionally, the Company entered into various Subscription agreements with unrelated parties and issued 40,000 shares of common stock in consideration for payments of $10,000.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; 2011 Omnibus Long-Term Incentive Plan&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On March 9, 2011, the Company adopted, subject to shareholder approval, the 2011 Omnibus Long-Term Incentive Plan (the "Plan") to offer competitive long-term incentive compensation opportunities as well as to align the interests of the participants with those of the Company&amp;#39;s shareholders.&amp;nbsp;&amp;nbsp;Under the Plan, stock options, stock appreciation rights, restricted shares, and performance shares are to be awarded at the discretion of the Compensation Committee to selected officers, employees, consultants and eligible directors of the Company.&amp;nbsp;&amp;nbsp;&amp;nbsp;In order for the Plan to become effective, shareholder approval must be obtained on or before March 8, 2012.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Warrants&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; A summary of the status of the warrants granted for the nine month period ended September 30, 2011 and for the year ended December 31, 2010 and changes during the periods then ended is presented below:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="text-align: left"&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="8"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; For the Year Ended December 31, 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="8"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; For the Nine Months Ended&amp;nbsp;September 30, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Weighted Average Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Shares&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Weighted Average Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Outstanding at beginning of period&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1,299,769&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.54&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Outstanding at beginning of period&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;3,230,369&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.07&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Granted&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1,930,600&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.75&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Granted&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;5,708,299&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.68&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Exercised&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Exercised&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Forfeited&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;-&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Outstanding at end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;3,230,369&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.07&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="26%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Outstanding at end of period&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;8,938,668&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.82&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="text-align: left"&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td valign="bottom" colspan="14"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; As of September 30, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="6"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; As of September 30, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="14"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Warrants Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="6"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center; TEXT-INDENT: 0pt"&gt; Warrants Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Weighted-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Weighted-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Weighted-&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Range of&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: center" valign="bottom" colspan="2"&gt; Remaining&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Number&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Average&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Exercise Prices&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Contract Life&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Exercisable&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Exercise Price&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" colspan="2"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.001&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;299,769&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.3&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.001&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;299,769&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.001&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.25&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;200,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;4.1&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.25&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;200,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.25&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.40&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;999,999&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2.8&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.40&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;999,999&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.40&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.50&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2,694,450&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2.7&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.50&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2,694,450&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.50&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.60&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;475,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;4.8&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.60&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;475,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.60&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.75&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;200,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;4.1&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.75&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;200,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.75&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.00&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;3,069,450&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2.6&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.00&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;3,069,450&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.00&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2.00&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1,000,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1.3&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2.00&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;1,000,000&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2.00&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.001- 2.00&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;8,938,668&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;2.7&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.82&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;8,938,668&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;0.82&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="SubsequentEventsTextBlock.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 9 - SUBSEQUENT EVENTS&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; In October of 2011, $22,000 of the principal balance due on the April 4, 2011 8% convertible promissory note was converted into 180,311 shares of common stock.&amp;nbsp;&amp;nbsp;The Company also paid the balance of $295,002 and all accrued interest related to the notes payable from the first quarter of 2011.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On October 7, the Company executed a convertible promissory note with an unrelated party in the amount of $30,000.&amp;nbsp;&amp;nbsp;The note matures nine months from the date of issuance and accrues interest at 8% per annum.&amp;nbsp;&amp;nbsp;The Note holder has the right to convert any outstanding principal and accrued interest payable into shares of the Company&amp;#39;s common stock at a 50% discount on the market value.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Company has evaluated all subsequent events from the balance sheet date through the date of this filing and with the exception of the items mentioned above there are no events to disclose.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:TreasuryStockValue id="TreasuryStockValue.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">-12039</us-gaap:TreasuryStockValue>
  <us-gaap:TreasuryStockValue id="TreasuryStockValue.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">-12039</us-gaap:TreasuryStockValue>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="WeightedAverageNumberOfSharesOutstandingBasic.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="UShares" decimals="0">57505852</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="WeightedAverageNumberOfSharesOutstandingBasic.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="UShares" decimals="0">53447612</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="WeightedAverageNumberOfSharesOutstandingBasic.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="UShares" decimals="0">35677399</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="WeightedAverageNumberOfSharesOutstandingBasic.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="UShares" decimals="0">34893037</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <wndm:AccruedInterestRelatedParties id="AccruedInterestRelatedParties.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">101366</wndm:AccruedInterestRelatedParties>
  <wndm:AccruedInterestRelatedParties id="AccruedInterestRelatedParties.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">45299</wndm:AccruedInterestRelatedParties>
  <wndm:AccruedInterestRelatedParties1 id="AccruedInterestRelatedParties1.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">92837</wndm:AccruedInterestRelatedParties1>
  <wndm:AccruedInterestRelatedParties1 id="AccruedInterestRelatedParties1.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">101815</wndm:AccruedInterestRelatedParties1>
  <wndm:AccruedInterests1 id="AccruedInterests1.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">108155</wndm:AccruedInterests1>
  <wndm:AccruedInterests1 id="AccruedInterests1.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">23945</wndm:AccruedInterests1>
  <wndm:DebtRelatedExpense1 id="DebtRelatedExpense1.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">-586693</wndm:DebtRelatedExpense1>
  <wndm:DebtRelatedExpense1 id="DebtRelatedExpense1.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-4086634</wndm:DebtRelatedExpense1>
  <wndm:DebtRelatedExpense1 id="DebtRelatedExpense1.3015.0.0" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" decimals="0">-206250</wndm:DebtRelatedExpense1>
  <wndm:DebtRelatedExpense1 id="DebtRelatedExpense1.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-206250</wndm:DebtRelatedExpense1>
  <wndm:DeferredFinancingCosts id="DeferredFinancingCosts.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">34227</wndm:DeferredFinancingCosts>
  <wndm:DeferredFinancingCosts id="DeferredFinancingCosts.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">294000</wndm:DeferredFinancingCosts>
  <wndm:FinancingAcquisitionOfNoteReceivableAndRelatedDebt id="FinancingAcquisitionOfNoteReceivableAndRelatedDebt.3014.0.0" xsi:nil="true" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:FinancingAcquisitionOfNoteReceivableAndRelatedDebt id="FinancingAcquisitionOfNoteReceivableAndRelatedDebt.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">400000</wndm:FinancingAcquisitionOfNoteReceivableAndRelatedDebt>
  <wndm:GainLossOnJointVenture id="GainLossOnJointVenture.3013.0.0" contextRef="from-2011-07-01-to-2011-09-30.3013.0.0.0" unitRef="USD" decimals="0">11655</wndm:GainLossOnJointVenture>
  <wndm:GainLossOnJointVenture id="GainLossOnJointVenture.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">11655</wndm:GainLossOnJointVenture>
  <wndm:GainLossOnJointVenture id="GainLossOnJointVenture.3015.0.0" xsi:nil="true" contextRef="from-2010-07-01-to-2010-09-30.3015.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:GainLossOnJointVenture id="GainLossOnJointVenture.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:INTANGIBLEASSETS id="INTANGIBLEASSETS.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 6 - INTANGIBLE ASSETS&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Marketing Contacts&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On September 17, 2009, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement"), whereby BioPharma became a wholly-owned subsidiary of the Company.&amp;nbsp;&amp;nbsp;Pursuant to the terms of the Merger Agreement, 4,500,000 shares of the Company&amp;#39;s common stock were issued in exchange for all the outstanding common stock of BioPharma.&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Prior to the Merger Agreement, BioPharma entered into a 50% joint venture with A&amp;amp;Z Pharmaceutical, LLC ("A&amp;amp;Z") to form Pharma Technology International, LLC ("Pharma Tech").&amp;nbsp;&amp;nbsp;&amp;nbsp;A&amp;amp;Z is a privately-held wholesale distributor of pharmaceuticals formed in 1997. A&amp;amp;Z&amp;#39;s customer base includes tertiary hospitals, medical institutions, and governmental agencies located in the United States, South America, Europe and the Middle East.&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Pharma Tech entered into a Distribution Agreement (the "Distribution Agreement") to market, distribute and sell the WCI wound care products in the Middle East through existing A&amp;amp;Z distribution channels. The agreement, which covers 20 countries throughout the Middle East and Northern Africa, requires Pharma Tech to sell a minimum of $500,000 of the products each year of the five year agreement to maintain the exclusive right to sell the products.&amp;nbsp;&amp;nbsp;The operations of Pharma Tech to date have been minimal, and although Pharma Tech placed orders with WCI during 2010 for sales of the CellerateRX product in Lebanon, the minimum sales amount was not obtained.&amp;nbsp;&amp;nbsp;Our recent experience with international markets indicates that the sales process is much lengthier than first anticipated.&amp;nbsp;&amp;nbsp;As a result, the impact on sales figures from the contacts in the Middle East can&amp;#39;t be accurately evaluated until the sales team has had 24 months to work through the government regulations regarding the sale of medical products.&amp;nbsp;&amp;nbsp;&amp;nbsp;Although other distributors are now able to sell the product in the region, the sales pipeline already developed by Pharma Tech in year one has resulted in additional sales in 2011.&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; As part of the BioPharma acquisition, the formula for a shingles based product was obtained which is only at the idea stage and no determination has been made as to whether the formula can be developed cost effectively into a product. According to the guidance in ASC Topic No. 805-20-25-1, identifiable assets should be recognized separately from goodwill and there was no value assigned to this formula.&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; The BioPharma transaction has been accounted for as a business combination based on the guidance in ASC Topic No. 805.&amp;nbsp;&amp;nbsp;The financial statements of BioPharma have been consolidated with those of the Company and an intangible asset was recorded in the amount of $4,187,815 or approximately $.93 per common share issued on the date of acquisition.&amp;nbsp;&amp;nbsp;The value of the intangible asset&amp;nbsp;&amp;nbsp;assigned to the marketing contacts recorded by the Company is based on Level 3 input to our&lt;/font&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; valuation methodology, which consists of models with significant unobservable market parameters.&amp;nbsp;&amp;nbsp;We utilized a discounted cash flow analysis based on sales projections from the Distribution Agreement adjusted for the associated costs.&amp;nbsp;&amp;nbsp;According to ASC Topic No. 805-20-55-27, a customer relationship acquired in a business combination that does not arise from a contract may be an identifiable asset separate from goodwill.&amp;nbsp;&amp;nbsp;&amp;nbsp;The estimated useful life of the intangible asset is ten years based on the automatic renewable five year term of the&amp;nbsp;&amp;nbsp;Distribution Agreement.&amp;nbsp;&amp;nbsp;The amount amortized for the nine months ended September 30, 2011 was $314,087 resulting in a balance of&amp;nbsp;&amp;nbsp;$837,563 in accumulated amortization as of&amp;nbsp;&amp;nbsp;September 30, 2011.&amp;nbsp;&amp;nbsp;The balance of the intangible asset, net of accumulated amortization, is $3,350,252 as of September 30, 2011.&lt;/font&gt;&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Patent&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On September 29, 2009, the Company entered into an Asset Purchase Agreement (the "Agreement"), whereby the Company acquired a patent from Resorbable Orthopedic Products, LLC, a New Jersey limited liability company ("Resorbable NJ") in exchange for 500,000 shares of the Company&amp;#39;s common stock and the assumption of a legal fee payable in the amount of $47,595 which is related to the patent.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Based on the guidance in ASC Topic No. 350-30, the patent was recorded as an intangible asset of $462,715, or approximately $.93 per share, plus $47,595 for the assumed liability.&amp;nbsp;&amp;nbsp;The intangible asset is being amortized over an estimated ten year useful life. The amount amortized for the nine months ended September 30, 2011 was $38,272, resulting in a balance of&amp;nbsp;&amp;nbsp;$102,062 in accumulated amortization as of September 30, 2011.&amp;nbsp;&amp;nbsp;&amp;nbsp;The balance of the intangible asset, net of accumulated amortization, is $408,248 as of September 30, 2011.&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Upon closing of the asset sale by Resorbable NJ, the managers of this New Jersey limited liability company abandoned the name "Resorbable Orthopedic Products, LLC." RSI-ACQ Acquisition, LLC, a Texas limited liability company owned by the Company and formed on August 24, 2009, assumed the name of "Resorbable Orthopedic Products, LLC" in Texas.&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The activity for the intangible accounts is summarized below:&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;div style="text-align: left"&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; September 30, 2011&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%" colspan="2"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; December 31, 2010&lt;/div&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="bottom" width="70%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Patent&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;510,310&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;510,310&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;(102,062&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;(63,790&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Patent, net of accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;408,248&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;446,520&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="bottom" width="70%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: right" valign="bottom" width="12%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="bottom" width="70%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Marketing contacts&lt;/div&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;4,187,815&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;4,187,815&lt;/td&gt; &lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;(837,563&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;(523,476&lt;/td&gt; &lt;td style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;)&lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="70%" align="left"&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Marketing contacts,&amp;nbsp;&amp;nbsp;net of accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;3,350,252&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;3,664,339&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="70%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Total intangibles, net of accumulated amortization&lt;/div&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;3,758,500&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;$&lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; TEXT-ALIGN: right" valign="bottom" width="12%"&gt;4,110,859&lt;/td&gt; &lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</wndm:INTANGIBLEASSETS>
  <wndm:NonCashDebtRelatedCosts id="NonCashDebtRelatedCosts.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">250000</wndm:NonCashDebtRelatedCosts>
  <wndm:NonCashDebtRelatedCosts id="NonCashDebtRelatedCosts.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">455306</wndm:NonCashDebtRelatedCosts>
  <wndm:NOTESPAYABLE id="NOTESPAYABLE.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 5 - NOTES PAYABLE&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Notes Payable - Related Parties&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Funds are advanced to the Company from various related parties including Scott A. Haire, the Company&amp;#39;s CEO, and entities controlled by him.&amp;nbsp;&amp;nbsp;Other shareholders may fund the Company as necessary to meet working capital requirements and expenses.&amp;nbsp;&amp;nbsp;The following is a summary of amounts due to related parties, including terms of the debt, and the interest accrued as of September 30, 2011:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Related party&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Nature of relationship&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Terms of the agreement&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Principal amount&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Accrued Interest&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; H.E.B., LLC, a Nevada&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; limited liability company&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Scott Haire is the managing&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; member of H.E.B., LLC.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="29%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Series of funds advanced under three separate,&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; unsecured lines of credit totaling $1.3 million at&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; 10% per annum; no maturity date; unused lines&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; available at September 30, 2011 total $1,147,988.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $&amp;nbsp;&amp;nbsp;&amp;nbsp;152,012&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $42,236&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Commercial&amp;nbsp;&amp;nbsp;Holding&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; AG, LLC&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Commercial Holding AG, LLC&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; has provided previous lines of&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; credit to affiliates of WMT.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="29%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Unsecured notes with interest accrued at rates of&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; 8% and 10% per annum until paid in full with no&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; maturity date.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;199,145&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; 49,247&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; MAH Holding, LLC&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; MAH Holding, LLC has&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; provided previous lines of&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; credit to affiliates of WMT.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="29%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Unsecured notes with interest accrued at 10% per&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; annum until paid in full with no maturity date.&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; 68,420&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; 1,354&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; TOTAL&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="29%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $&amp;nbsp;&amp;nbsp;&amp;nbsp;419,577&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $92,837&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; As mentioned in Note 3 - "Significant Transactions," the principal balance of the $400,000 WMT Note due to VHGI for the purchase of assets in February 2010 was paid in full as of March 31, 2011. The remaining $31,036 of accrued interest payable related to the WMT note due as of March 31, 2011 was paid in April of 2011.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Notes Payable&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On December 28, 2010, the company issued a note in the amount of $50,000 to an unrelated party. The note and interest, accrued at 12%, had a maturity date of February 28, 2011.&amp;nbsp;&amp;nbsp;In consideration of the note, the Company issued 160,000 shares of common stock valued at $56,000.&amp;nbsp;&amp;nbsp;The Company recorded the value of the common stock and $3,100 of issuance costs as a loan origination fee in the fourth quarter of 2010. The entire balance due on this note, including accrued interest, was paid in full in February of 2011.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; In the first quarter of 2011, the Company issued debt in the amount of $1,660,000 to various unrelated parties.&amp;nbsp;&amp;nbsp;The terms of the debt are as follows:&amp;nbsp;&amp;nbsp;(i) interest accrues at 10% per annum; (ii) maturity date is six months from the date of issuance; and (iii) debt is secured by a first priority interest in the inventory of the Company and is senior to all other obligations of the Company.&amp;nbsp;&amp;nbsp;&amp;nbsp;Additionally, the Company agreed to issue a total of 4,150,000 shares of common stock to the lenders at a price of $0.01 per share, the value of which reduced the balance of the notes payable. The Company issued 3,900,000 of the shares in the first quarter of 2011 and recorded the difference between the fair market value of the stock and the $39,000 reduction in notes payable as a loan origination fee in the amount of $2,276,250.&amp;nbsp;&amp;nbsp;The remaining 250,000 shares were issued in the second quarter of 2011 and a loan origination fee in the amount of $153,750 was recorded in addition to a $2,500 reduction to the notes payable.&amp;nbsp;&amp;nbsp;The total owed to these lenders as of September 30, 2011 is $295,002.&amp;nbsp;&amp;nbsp;The accrued interest balance as of this same date is $9,928.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On January 11, 2011 the Company executed a promissory note in the amount of $200,000 to an unrelated party.&amp;nbsp;&amp;nbsp;In consideration for the note, the Company issued 200,000 shares of common stock valued at $112,000 as a loan origination fee.&amp;nbsp;&amp;nbsp;The note payable and interest, accrued at 10%, was paid in full in February 2011.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On January 10, 2011, the Company executed two promissory notes to two unrelated parties in the amount of $50,000 each.&amp;nbsp;&amp;nbsp;The notes and interest, accrued at 24% per annum, are due two months from the issuance date. An additional note payable in the amount of $100,000 with the same terms was issued to a third party on January 14, 2011.&amp;nbsp;&amp;nbsp;The Company issued a total of 400,000 shares of common stock in the first quarter for a total reduction to the notes payable in the amount of $8,000.&amp;nbsp;&amp;nbsp;The remaining note balances including $8,000 of accrued interest were paid in full as of March 31, 2011.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On May 27, 2011, the Company executed a senior promissory note in the amount of $125,000 with an unrelated party.&amp;nbsp;&amp;nbsp;In consideration for the note, the Company agreed to issue 370,000 shares of common stock valued at $234,950 as a loan origination fee.&amp;nbsp;&amp;nbsp;The shares of stock were issued in the third quarter and as of September 30, 2011 the note balance is paid in full.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On June 3, 2011, the Company executed a short-term promissory note in the amount of $75,000 to an unrelated party. The note was repaid in full as of June 30, 2011.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On June 17, 2011, the Company executed three senior promissory notes to unrelated parties in the total amount of $250,000. The terms of the debt are as follows: (i) interest accrues at 12% per annum; (ii) maturity date is three months from the date of issuance; (iii) the Company will issue 475,000 shares of common stock; and (iv) the Company will issue to the Lenders five-year warrants to purchase a total of 475,000 shares of common stock at a price of $0.60 per share.&amp;nbsp;&amp;nbsp;The 475,000 Common Shares were issued in the third quarter of 2011 and the fair market value of the stock has been recorded as a loan origination fee in the amount of $332,750.&amp;nbsp;&amp;nbsp;The Company measured the fair value of the warrants and recorded a 100% discount against the principal of the notes. The discount is being accreted to interest expense over the term of the notes using the effective interest method.&amp;nbsp;&amp;nbsp;&amp;nbsp;In September of 2011, the Company executed an agreement extending the due date of one of the notes in the amount of $62,500 to October 31, 2011.&amp;nbsp;&amp;nbsp;The Company also executed two additional agreements extending the due dates of the remaining notes to November 31, 2011.&amp;nbsp;&amp;nbsp;As of September 30, 2011, $245,000 of principal and $8,430 of accrued interest remains due.&amp;nbsp;&amp;nbsp;The discount has been fully amortized as of this same date.&amp;nbsp;&amp;nbsp;As of the date of this filing, $61,250 of principal related to these notes is past due.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On September 2, 2011, the Company executed two short-term promissory notes with two unrelated parties for a total of $55,000.&amp;nbsp;&amp;nbsp;&amp;nbsp;Both notes were paid in full as of September 30, 2011.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Convertible Notes Payable&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; OCTOBER 28, 2010 CONVERTIBLE NOTES&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On October 28, 2010, the Company executed four convertible promissory notes to unrelated parties with a combined total face amount of $390,000 and a funded amount of $250,000.&amp;nbsp;&amp;nbsp;The maturity date for each of the notes was February 28, 2011 and there was no stated interest rate.&amp;nbsp;&amp;nbsp;&amp;nbsp;In accordance with ASC Topic No. 470-20-25-4, the intrinsic value of the embedded beneficial conversion feature present in a convertible instrument shall be recognized separately at issuance by allocating a portion of the debt equal to the intrinsic value of that feature to additional paid in capital.&amp;nbsp;&amp;nbsp;A discount in the amount of $202,800 was calculated as the total value of the beneficial conversion feature, which is being amortized over the term of the note.&amp;nbsp;&amp;nbsp;The remaining unamortized balance as of December 31, 2010 was $65,333 and this amount has been amortized and recorded as interest expense in the first quarter of 2011.&amp;nbsp;&amp;nbsp;In addition, the discount amount of $140,000 has also been amortized over the term of the loan.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;The unamortized balance as of December 31, 2010 was $94,640 and this amount was fully amortized and recorded as interest expense in the first quarter 2011.&amp;nbsp;&amp;nbsp;Upon the February 28, 2011 maturity date, $275,000 of the balance owed was converted into 1,100,000 shares of common stock.&amp;nbsp;&amp;nbsp;&amp;nbsp;An additional $20,000 of the balance owed was arranged to be converted into 80,000 shares of common stock which were issued in the second quarter of 2011. The remaining balance owed on the notes was paid in cash in March of 2011 and the balance owed as of September 30, 2011 is zero.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; As consideration for making the above mentioned loans, a combined total of 800,000 warrants were issued to the lenders to purchase shares of the Company&amp;#39;s common stock.&amp;nbsp;&amp;nbsp;The warrants have an exercise price of $.25, $.50, $.75 and $1.00 in increments of 200,000, respectively.&amp;nbsp;&amp;nbsp;All the warrants expire 5 years from the date of issuance. The fair value of the warrants on the date of issuance was calculated using the Black-Scholes option pricing model at each of the above mentioned exercise prices.&amp;nbsp;&amp;nbsp;The $304,000 value of the warrants was recorded as a capital contribution and loan origination expense at the date of issuance.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; DECEMBER 28, 2010 CONVERTIBLE NOTE&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On December 28, 2010, a convertible promissory note was executed in the amount of $50,000 to an unrelated party.&amp;nbsp;&amp;nbsp;The note, which accrues interest at 8% per annum, has a maturity date of September 30, 2011.&amp;nbsp;&amp;nbsp;The note agreement included a $3,000 discount which is being amortized over the nine-month term of the loan.&amp;nbsp;&amp;nbsp;The note is convertible into shares of the Company&amp;#39;s common stock at a 45% discount.&amp;nbsp;&amp;nbsp;In July of 2011, the Company issued 235,603 shares of common stock in payment of the principal balance and all accrued interest.&amp;nbsp;&amp;nbsp;The Company also amortized the remaining discount of $985 and recorded a loss on the conversion in the amount of $52,066.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; APRIL 4 &amp;amp; MAY 20, 2011 CONVERTIBLE NOTES&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On April 4, 2011 and May 20, 2011, the Company executed convertible promissory notes with the same terms to the same unrelated party in the amounts of $50,000 and $30,000, respectively.&amp;nbsp;&amp;nbsp;The notes mature nine months from the date of issuance and accrue interest at 8% per annum.&amp;nbsp;&amp;nbsp;In the event of default the interest rate will increase to 22%. The Note holder has the right to convert any outstanding principal and accrued interest payable, at a conversion price per share equal to 55% of the average of the three lowest closing prices of the Company&amp;#39;s common stock for the 10 day trading period ending on the latest complete trading day before the conversion date.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; In accordance with ASC Topic No. 470-20-25-4, the Company recognized the intrinsic value of the embedded beneficial conversion feature of $77,418 as additional paid-in capital and an equivalent discount that reduced the carrying value of the convertible notes. The discount is being accreted to interest expense over the term of the notes.&amp;nbsp;&amp;nbsp;The remaining unamortized balance as of September 30, 2011 is $32,201.&amp;nbsp;&amp;nbsp;The accrued interest payable on the notes as of the same date is $2,691.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; JUNE 9, 2011 CONVERTIBLE NOTES&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On June 9, 2011, the Company executed three convertible promissory notes to unrelated parties in the total amount of $300,000.&amp;nbsp;&amp;nbsp;The notes accrue interest at 10% and mature six months from the issue date.&amp;nbsp;&amp;nbsp;The notes are convertible into shares of the Company&amp;#39;s common stock at the lesser of $0.40 per share or 50% of the lowest bid price in the five days preceding the conversion date. In addition, the Company issued to such investors a total of 999,999 three-year detachable warrants to purchase shares of common stock at an exercise price of $0.40 per share.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; In accordance with ASC 470-20, the proceeds of $300,000 were allocated based on the relative fair values of the convertible notes and the detachable warrants at the time of issuance. The Company allocated $198,876 of the proceeds to the detachable warrants and recorded an equivalent discount.&amp;nbsp;&amp;nbsp;The Company then recognized the intrinsic value of the embedded beneficial conversion feature of $101,124 as additional-paid-in capital and an equivalent discount for a total discount of $300,000. The discount is being accreted to interest expense over the term of the notes using the effective interest method. The unamortized discount balance as of September 30, 2011 is $178,535. The accrued interest payable balance as of the same date is $9,370.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; JUNE 21, 2011 CONVERTIBLE NOTE&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; On June 21, 2011, the Company entered into a note and warrant purchase agreement whereby the Company issued and sold, and an unrelated party purchased: (i) a convertible promissory note of the Company in the principal amount of $560,000 bearing a 12% interest rate (ii) and two warrants, each giving the holders the right to purchase 250,000 shares of common stock. Additionally upon closing, the Company issued to the lender 100,000 shares of common stock of the Company valued at $60,000 as a loan origination fee. The maturity date of the note is June 21, 2015.&amp;nbsp;&amp;nbsp;In consideration for the issuance and sale of the note and warrants, the lender paid cash in the amount of $250,000 and issued five $50,000 5% secured notes, each with a maturity date 49 months from the initial funding date.&amp;nbsp;&amp;nbsp;The $60,000 variance between the face value of the note and the funds received represents a 9.1% original issue discount of $50,000 and a $10,000 payment obligation with respect to certain fees and expenses.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; The note is convertible into shares of the Company&amp;#39;s common stock, at the option of the lender, at a price per share equal to (a) the principal and interest to be converted divided by (b) 70% of the lowest trade price for the thirty (30) trading days immediately preceding conversion. The principal and interest subject to conversion under the note shall be eligible for conversion in tranches, as follows: (1) an initial tranche in an amount equal to $310,000 and any interest or fees accrued thereon, and (5) five additional subsequent tranches each in an amount equal to $50,000 and any interest or fees accrued thereon.&amp;nbsp;&amp;nbsp;The first tranche of $310,000, representing the amounts paid by the investor upon the closing of the transaction, may be converted at the lender&amp;#39;s option at any time.&amp;nbsp;&amp;nbsp;The lender&amp;#39;s right to convert any of the subsequent tranches is conditioned upon the lender&amp;#39;s payment of the corresponding 5% secured note receivable (see note 4).&amp;nbsp;&amp;nbsp;Accordingly, principal and interest under the note may only be converted by the lender in proportion to the amounts paid under each of the 5% secured notes.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Both warrants are exercisable for a period of five years from the initial funding date, and entitle the investor to purchase 250,000 shares of common stock.&amp;nbsp;&amp;nbsp;The first warrant is exercisable at $0.50 per share and the second at $1.00 per share.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Company measured the fair value of the warrants and the beneficial conversion feature of the note and recorded a discount against the principal of the note. The discount is being accreted to interest expense over the term of the notes using the effective interest method. The unamortized discount balance as of September 30, 2011 is $567,830.&amp;nbsp;&amp;nbsp;The principal balance and accrued interest payable balance due on the note as of the same date is $560,000 and $20,804 respectively.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; JULY 13 &amp;amp; AUGUST 18, 2011 CONVERTIBLE NOTES&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On July 13, 2011 and August 18, 2011, the Company executed convertible promissory notes with the same terms to the same unrelated party in the amounts of $40,000 and $50,000, respectively.&amp;nbsp;&amp;nbsp;The notes mature nine months from the date of issuance and accrue interest at 8% per annum.&amp;nbsp;&amp;nbsp;In the event of default the interest rate will increase to 22%. The Note holder has the right to convert any outstanding principal and accrued interest payable, into shares of the Company&amp;#39;s common stock at a conversion price per share equal to 50% of the average of the three lowest closing prices of the Company&amp;#39;s common stock for the 10-day trading period ending on the latest complete trading day before the conversion date.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; In accordance with ASC Topic No. 470-20-25-4, the Company recognized the intrinsic value of the embedded beneficial conversion feature of $88,542 as additional paid-in capital and an equivalent discount that reduced the carrying value of the convertible notes. The discount is being accreted to interest expense over the term of the notes.&amp;nbsp;&amp;nbsp;The remaining unamortized balance as of September 30, 2011 is $70,429.&amp;nbsp;&amp;nbsp;The accrued interest payable on the notes as of the same date is $1,475.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Debentures&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On March 30, 2010, the Company entered into a Securities Purchase Agreement and, pursuant to this agreement, a total of $1,000,000 in principal amount of convertible debentures (the "Debentures"), with a maturity date of March 2013, may be sold to investors.&amp;nbsp;&amp;nbsp;The Debentures may be converted into shares of the Company&amp;#39;s common stock at a conversion price equal to seventy percent (70%) of the lowest closing bid price per share for the twenty (20) trading days immediately preceding the date of conversion; provided that no holder may convert Debentures into, nor shall the Company issue to such holder, shares of common stock to the extent that the conversion would result in a holder and its affiliates together beneficially owning more than 4.99% of the then issued and outstanding shares of the Company&amp;#39;s common stock.&amp;nbsp;&amp;nbsp;&amp;nbsp;This ownership restriction may be waived, however, by a holder upon sixty-one (61) days prior written notice.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Debentures may be redeemed by the Company at any time or from time to time at a price equal to (x) one hundred twenty percent (120%) of the principal amount of the Debenture if the Debenture is called for redemption prior to the expiration of six months from the issuance date, or one hundred thirty one percent (131%) if called for redemption thereafter, plus (y) interest accrued through the day immediately preceding the date of redemption.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; During 2010, the Company issued Debentures in the aggregate principal amount of $695,000.&amp;nbsp;&amp;nbsp;In accordance with ASC Topic No. 470-20-25-4, the intrinsic value of the embedded beneficial conversion feature was calculated and a a discount in the amount of $297,857 was recorded as the total value of the beneficial conversion feature. The discount is being amortized over the three year term of the Debentures. The unamortized discount balance at September 30, 2011 is $185,351 and the debt balance, net of the discount, is $509,649.&amp;nbsp;&amp;nbsp;In addition, debt issuance costs of $102,850 have been deferred and are being amortized over the term of the debt.&amp;nbsp;&amp;nbsp;As of September 30, 2011 the unamortized balance of deferred loan costs is $63,511. The Company accrues interest expense on the debentures at 6% per annum, and as of September 30, 2011 the balance of accrued interest related to the Debentures is $55,457.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</wndm:NOTESPAYABLE>
  <wndm:NotesPayableNetOfDiscount id="NotesPayableNetOfDiscount.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">721007</wndm:NotesPayableNetOfDiscount>
  <wndm:NotesPayableNetOfDiscount id="NotesPayableNetOfDiscount.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">327060</wndm:NotesPayableNetOfDiscount>
  <wndm:NOTESRECEIVABLE id="NOTESRECEIVABLE.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 4 - NOTES RECEIVABLE&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; &lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Notes Receivable&lt;/font&gt; - &lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;Related Parties&lt;/font&gt;&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The following is a summary of amounts due from related parties, including accrued interest separately recorded, as of September 30, 2011:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Related party&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Nature of relationship&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="27%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Terms of the agreement&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Principal amount&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: center; TEXT-INDENT: 0pt"&gt; Accrued Interest&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="27%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; H.E.B., LLC, a Nevada&lt;/div&gt; &lt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; limited&lt;/font&gt; &lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; liability company&lt;/font&gt;&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Scott Haire is the managing&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; member of HEB.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="27%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Unsecured $800,000 line of credit due on demand&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; with interest rate of 10% per annum.&amp;nbsp;&amp;nbsp;&amp;nbsp;Available&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; line as of September 30, 2011 is $760,867.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="10%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;39,133&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $1,171&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="27%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; VHGI Holdings, Inc.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Scott Haire is a director and officer&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; of WMT and VHGI.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="27%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Unsecured note with interest accrued at rate of&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; 10% per annum and is due on demand.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="10%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;45,664&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; 4,418&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="top" width="14%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="27%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="10%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="lightcyan"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; MAH Holding, LLC&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; MAH Holding, LLC has provided&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; previous lines of credit to affiliates&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; &amp;nbsp;of WMT.&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="27%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Unsecured note with interest accrued at 10%&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; per annum and is due on demand.&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; &amp;nbsp;&amp;nbsp;1,019,211&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; 95,777&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr bgcolor="white"&gt; &lt;td valign="top" width="14%" align="left"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; TOTAL&lt;/div&gt; &lt;/td&gt; &lt;td valign="top" width="19%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td valign="top" width="27%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt; &amp;nbsp;&lt;/font&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="10%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $1,104,008&lt;/div&gt; &lt;/td&gt; &lt;td style="BORDER-BOTTOM: black 4px double" valign="top" width="9%" align="right"&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: right; TEXT-INDENT: 0pt"&gt; $101,366&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Notes Receivable&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Private Access Note, in the amount of $1,500,000, is with an unrelated company and the loan bears interest at 9% per annum from the day of purchase to the maturity date of July 31, 2013, with $227,152 of interest accrued as of September 30, 2011.&amp;nbsp;&amp;nbsp;According to the terms of the Assignment and Assumption Agreement between VHGI ("Assignor"), Private Access, Inc. ("Private Access") and the Company ("Assignee"), Assignor assigned all rights, title and interest in the Private Access Note, including the right to serve as collateral agent for the collateral pledged as security by Private Access to the Assignee.&amp;nbsp;&amp;nbsp;Under the terms of the Security Agreement dated August 3, 2009, which was assigned to the Company by Assignor, the Company, along with other investors, holds pro rata security interests in all property of Private Access including its intellectual property.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; The Company has five $50,000 5% secured notes, with the same unrelated party for a total balance of $250,000.&amp;nbsp;&amp;nbsp;The notes were received as part of the June 21, 2011 note payable and warrant purchase agreement (see note 5).&amp;nbsp;&amp;nbsp;Each $50,000 5% secured note receivable has a maturity date 49 months from the initial funding.&amp;nbsp;&amp;nbsp;As of September 30, 2011, the principal balance receivable on these notes is $250,000.&amp;nbsp;&amp;nbsp;&amp;nbsp;As of this same date, $4,236 of interest receivable has been accrued.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</wndm:NOTESRECEIVABLE>
  <wndm:PaymentsOnNotesPayableRelatedParties id="PaymentsOnNotesPayableRelatedParties.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">-1617852</wndm:PaymentsOnNotesPayableRelatedParties>
  <wndm:PaymentsOnNotesPayableRelatedParties id="PaymentsOnNotesPayableRelatedParties.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">-137181</wndm:PaymentsOnNotesPayableRelatedParties>
  <wndm:PreferredStockSeriesAParOrStatedValue id="PreferredStockSeriesAParOrStatedValue.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">5000000</wndm:PreferredStockSeriesAParOrStatedValue>
  <wndm:PreferredStockSeriesAParOrStatedValue id="PreferredStockSeriesAParOrStatedValue.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">5000000</wndm:PreferredStockSeriesAParOrStatedValue>
  <wndm:PreferredStockSeriesBParOrStatedValue id="PreferredStockSeriesBParOrStatedValue.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">75000</wndm:PreferredStockSeriesBParOrStatedValue>
  <wndm:PreferredStockSeriesBParOrStatedValue id="PreferredStockSeriesBParOrStatedValue.3018.0.0" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" decimals="0">75000</wndm:PreferredStockSeriesBParOrStatedValue>
  <wndm:ProceedsFromNotesPayableRelatedParties id="ProceedsFromNotesPayableRelatedParties.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">831363</wndm:ProceedsFromNotesPayableRelatedParties>
  <wndm:ProceedsFromNotesPayableRelatedParties id="ProceedsFromNotesPayableRelatedParties.3016.0.0" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" decimals="0">1355046</wndm:ProceedsFromNotesPayableRelatedParties>
  <wndm:ProceedsFromStockSubscriptionsPayable id="ProceedsFromStockSubscriptionsPayable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">5000</wndm:ProceedsFromStockSubscriptionsPayable>
  <wndm:ProceedsFromStockSubscriptionsPayable id="ProceedsFromStockSubscriptionsPayable.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:ProceedsFromStockSubscriptionsReceivable id="ProceedsFromStockSubscriptionsReceivable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">167001</wndm:ProceedsFromStockSubscriptionsReceivable>
  <wndm:ProceedsFromStockSubscriptionsReceivable id="ProceedsFromStockSubscriptionsReceivable.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:SeriesAPreferredStockValue id="SeriesAPreferredStockValue.3017.0.0" xsi:nil="true" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:SeriesAPreferredStockValue id="SeriesAPreferredStockValue.3018.0.0" xsi:nil="true" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:SeriesBPreferredStockValue id="SeriesBPreferredStockValue.3017.0.0" xsi:nil="true" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:SeriesBPreferredStockValue id="SeriesBPreferredStockValue.3018.0.0" xsi:nil="true" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:SIGNIFICANTTRANSACTIONS id="SIGNIFICANTTRANSACTIONS.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
&lt;div&gt; &lt;div&gt;&lt;!--StartFragment--&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; NOTE 3 - SIGNIFICANT TRANSACTIONS&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Asset and Business Acquisitions&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; On February 1, 2010, the Company entered into a purchase agreement with VHGI Holdings, Inc. ("VHGI"), a Delaware corporation.&amp;nbsp;&amp;nbsp;The total purchase price of $500,000, which consisted of $100,000 in cash and a promissory note in the principal amount of $400,000 (the "WMT Note"), was paid for certain assets and liabilities.&amp;nbsp;&amp;nbsp;Amounts recorded by the Company as a result of this transaction were the following:&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 36pt" align="right"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; a)&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; A long term asset has been recorded for the $1,500,000 Senior Secured Convertible Promissory Note Receivable issued by Private Access, Inc. (the "Private Access Note").&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="100%"&gt; &lt;tr valign="top"&gt; &lt;td style="WIDTH: 36pt" align="right"&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt; b)&amp;nbsp;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; A liability was incurred for the note payable obligation of $1,000,000, which included accrued interest incurred by VHGI in conjunction with the Private Access Note transaction. Subsequent to the purchase date, the Company negotiated payment of this debt with stock.&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; No value was assigned to the other assets included in the transaction, which were fully amortized intangibles, because no value was identified for these assets when determining the purchase price paid.&amp;nbsp;&amp;nbsp;These intangibles include intellectual property related to the prescription drug monitoring "Veriscrip" technology and the System Tray Notifier license owned by SeHealth.&amp;nbsp;&amp;nbsp;The purchased assets also included VHGI&amp;#39;s 100% membership interest in SeHealth.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; Scott A. Haire, the Company&amp;#39;s Chief Executive Officer ("CEO") and Chairman, also serves as Chairman and the Chief Financial Officer ("CFO") of VHGI.&amp;nbsp;&amp;nbsp;Based on shares outstanding as of the Annual Report on Form 10-K filed by VHGI for the year ended December 31, 2010, Mr. Haire beneficially owns, individually and through H.E.B., LLC, a Nevada limited liability company of which Mr. Haire is the managing member, 28% of the outstanding common stock of VHGI.&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: left; TEXT-INDENT: 0pt"&gt; Distribution Agreement&lt;/div&gt; &lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt; &lt;/div&gt; &lt;div style="DISPLAY: block; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt; text-align: justify; TEXT-INDENT: 0pt"&gt; As disclosed in our Form 8-K filing on April 14, 2011, Juventas, LLC ("Juventas") purchased the exclusive right to sell the CellerateRX powder products in North America.&amp;nbsp;&amp;nbsp;Juventas is an affiliate of Biomet Texas, Ltd., the largest Biomet distributor. This multi-year agreement has escalating sales requirements for Juventas to retain such exclusive rights.&amp;nbsp;&amp;nbsp;We received an &amp;#39;upfront&amp;#39; non-refundable payment of $500,000 from Juventas for this exclusive right to distribute CellerateRX powder, which was recorded as revenue in the first quarter of 2011.&lt;/div&gt; &lt;!--EndFragment--&gt;&lt;/div&gt; &lt;/div&gt;</wndm:SIGNIFICANTTRANSACTIONS>
  <wndm:StockIssuedAsPaymentOfExpenses id="StockIssuedAsPaymentOfExpenses.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">388080</wndm:StockIssuedAsPaymentOfExpenses>
  <wndm:StockIssuedAsPaymentOfExpenses id="StockIssuedAsPaymentOfExpenses.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:StockIssuedForDebtRelatedCosts id="StockIssuedForDebtRelatedCosts.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">3338200</wndm:StockIssuedForDebtRelatedCosts>
  <wndm:StockIssuedForDebtRelatedCosts id="StockIssuedForDebtRelatedCosts.3016.0.0" xsi:nil="true" contextRef="from-2010-01-01-to-2010-09-30.3016.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:StockSubscriptionPayable id="StockSubscriptionPayable.3017.0.0" contextRef="as-of-2011-09-30.3017.0.0.0" unitRef="USD" decimals="0">5000</wndm:StockSubscriptionPayable>
  <wndm:StockSubscriptionPayable id="StockSubscriptionPayable.3018.0.0" xsi:nil="true" contextRef="as-of-2010-12-31.3018.0.0.0" unitRef="USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <wndm:SubscriptionsReceivableOffsetWithNotePayable id="SubscriptionsReceivableOffsetWithNotePayable.3014.0.0" contextRef="from-2011-01-01-to-2011-09-30.3014.0.0.0" unitRef="USD" decimals="0">72675</wndm:SubscriptionsReceivableOffsetWithNotePayable>
  <xbrli:unit id="UShares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USD">
    <xbrli:measure>ISO4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="UPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>ISO4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="from-2011-07-01-to-2011-09-30.3013.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2011-01-01-to-2011-09-30.3014.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2011-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-07-01-to-2010-09-30.3015.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-07-01</xbrli:startDate>
      <xbrli:endDate>2010-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="from-2010-01-01-to-2010-09-30.3016.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2010-01-01</xbrli:startDate>
      <xbrli:endDate>2010-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2011-09-30.3017.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-12-31.3018.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="as-of-2010-09-30.3019.0.0.0">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000714256</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2010-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrl>
